Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy

被引：0
|
作者：
Gillison, Maura L. [1 ]
Blumenschein, George, Jr. [2 ]
Fayette, Jerome [3 ]
Guigay, Joel [4 ]
Colevas, A. Dimitrios [5 ]
Licitra, Lisa [6 ,7 ]
Harrington, Kevin J. [8 ]
Kasper, Stefan [9 ]
Vokes, Everett E. [10 ]
Even, Caroline [11 ]
Worden, Francis [12 ]
Saba, Nabil F. [13 ]
Iglesias Docampo, Lara Carmen [14 ]
Haddad, Robert [15 ]
Rordorf, Tamara [16 ]
Kiyota, Naomi [17 ]
Tahara, Makoto [18 ]
Lynch, Mark [19 ]
Kopit, Justin [19 ]
Ferris, Robert L. [20 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Ctr Leon Berard, Lyon, France
[4] FHU OncoAge, Ctr Antoine Lacassagne, Nice, France
[5] Stanford Univ, Stanford, CA 94305 USA
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] Univ Milan, Milan, Italy
[8] Inst Canc Res, Royal Marsden NHS Fdn Trust, London, England
[9] Univ Hosp, West German Canc Ctr, Essen, Germany
[10] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[11] Gustave Roussy, Villejuif, France
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Hosp Univ 12 Octubre, Madrid, Spain
[15] Dana Farber Harvard Canc Ctr, Boston, MA USA
[16] Univ Spital Zurich, Zurich, Switzerland
[17] Kobe Univ Hosp, Kobe, Hyogo, Japan
[18] Hosp East, Natl Canc Ctr, Kashiwa, Chiba, Japan
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [41] Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Kodama, Hiroyuki
    Kadowaki, Shigenori
    Ishizuka, Yasunobu
    Wakabayashi, Munehiro
    Sakakida, Tomoki
    Honda, Kazunori
    Masuishi, Toshiki
    Narita, Yukiya
    Taniguchi, Hiroya
    Ando, Masashi
    Kishikawa, Toshihiro
    Terada, Hoshino
    Beppu, Shintaro
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Hanai, Nobuhiro
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 480 - 488
  • [42] A COMPARISON OF PATIENT CHARACTERISTICS TREATED WITH NIVOLUMAB FOR RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN GERMANY AND THE USA
    von der Heyde, E.
    Welslau, M.
    Gauler, T.
    Rothnie, K.
    Waldenberger, D.
    Dietz, A.
    VALUE IN HEALTH, 2019, 22 : S536 - S536
  • [43] Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
    Argiris, A.
    Harrington, K.
    Tahara, M.
    Ferris, R. L.
    Gillison, M.
    Fayette, J.
    Daste, A.
    Koralewski, P.
    Nin, R. Mesia
    Saba, N. F.
    Mak, M.
    Avitia, M. A. Alvarez
    Guminski, A.
    Muller-Richter, U.
    Kiyota, N.
    Roberts, M.
    Khan, T. A.
    Miller-Moslin, K.
    Wei, L.
    Haddad, R. Robert
    ANNALS OF ONCOLOGY, 2021, 32 : S1310 - S1311
  • [44] ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN
    Suarez Rodriguez, J.
    Venkatachalam, M.
    Shaw, J. W.
    Contente, M.
    Polanco Sanchez, C.
    VALUE IN HEALTH, 2019, 22 : S448 - S448
  • [45] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
    Guigay, J.
    Lee, K-W.
    Patel, M. R.
    Daste, A.
    Wong, D. J.
    Goel, S.
    Gordon, M.
    Gutierrez, M.
    Balmanoukian, A.
    Le Tourneau, C.
    Mita, A.
    Vansteene, D.
    Keilholz, U.
    Schoffski, P.
    Grote, H. J.
    Zhou, D.
    Bajars, M.
    Penel, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S664 - S664
  • [47] CORRELATION BETWEEN QUALITY OF LIFE (QOL) OF PATIENTS TREATED WITH NIVOLUMAB IN RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) AND THEIR CAREGIVERS
    Baumstarck, K.
    Even, C.
    Grumberg, V
    Schwartz, D.
    Lahaye, J.
    Pointreau, Y.
    Ceruse, P.
    Babin, E.
    Fayette, J.
    Rondeau, V
    Cotte, F. E.
    Govart, A.
    Salas, S.
    Le Tourneau, C.
    VALUE IN HEALTH, 2023, 26 (12) : S474 - S474
  • [48] CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): A QUALITY OF LIFE (QOL) ANALYSIS OF THE EXTREME TRIAL
    Herrero, F. Rivera
    Hitt, R.
    Kawecki, A.
    Rottey, S.
    Peyrade, F.
    Vynnychenko, I.
    Curran, D.
    Kisker, O.
    Gross, A.
    Vermorken, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 219
  • [49] Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Fekih, M.
    Ferrand, F. R.
    Saada, E.
    Hamdan, D.
    Desmaris, R.
    Schilf, A.
    Guigay, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S568 - S569
  • [50] REAL WORLD TREATMENT PATTERNS FOR FIRST LINE (1L) RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PATIENTS
    Contente, M.
    Mtibaa, M.
    Hall, J.
    Bailey, H.
    Bailey, A.
    Di Rienzo, P.
    Polanco, C.
    Singh, P.
    VALUE IN HEALTH, 2019, 22 : S108 - S109
12345